{"id":"https://openalex.org/W1992055007","doi":"https://doi.org/10.1111/dom.12479","title":"Safety and efficacy of once\u2010weekly dulaglutide versus sitagliptin after 2 years in metformin\u2010treated patients with type 2 diabetes ( AWARD \u20105): a randomized, phase III study","display_name":"Safety and efficacy of once\u2010weekly dulaglutide versus sitagliptin after 2 years in metformin\u2010treated patients with type 2 diabetes ( AWARD \u20105): a randomized, phase III study","alternate_titles":[],"publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W1992055007","doi":"https://doi.org/10.1111/dom.12479","mag":"1992055007","pmid":"https://pubmed.ncbi.nlm.nih.gov/25912221","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5008205"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12479","doi":"https://doi.org/10.1111/dom.12479","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12479","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12479","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1992055007"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12479","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080916339","display_name":"Ruth S. Weinstock","orcid":"https://orcid.org/0000-0001-5859-5666","observed_orcids":["https://orcid.org/0000-0001-5859-5666"]},"institutions":[{"id":"https://openalex.org/I20388574","display_name":"SUNY Upstate Medical University","ror":"https://ror.org/040kfrw16","country_code":"US","type":"education","lineage":["https://openalex.org/I20388574"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. S. Weinstock","raw_affiliation_strings":["Endocrinology, Diabetes and Metabolism Upstate Medical University Syracuse NY USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Endocrinology, Diabetes and Metabolism Upstate Medical University Syracuse NY USA","institution_ids":["https://openalex.org/I20388574"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064287355","display_name":"Bruno Guerci","orcid":"https://orcid.org/0000-0002-6211-464X","observed_orcids":["https://orcid.org/0000-0002-6211-464X"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210100260","display_name":"Centre Hospitalier R\u00e9gional et Universitaire de Nancy","ror":"https://ror.org/016ncsr12","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210100260"]},{"id":"https://openalex.org/I90183372","display_name":"Universit\u00e9 de Lorraine","ror":"https://ror.org/04vfs2w97","country_code":"FR","type":"education","lineage":["https://openalex.org/I90183372"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B. Guerci","raw_affiliation_strings":["Diabetology, Metabolic Disease and Nutrition University of Lorraine, CIC Inserm ILCV, CHU Nancy France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetology, Metabolic Disease and Nutrition University of Lorraine, CIC Inserm ILCV, CHU Nancy France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210100260","https://openalex.org/I90183372"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061058170","display_name":"Guillermo E. Umpierrez","orcid":"https://orcid.org/0000-0002-3252-5026","observed_orcids":["https://orcid.org/0000-0002-3252-5026"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Umpierrez","raw_affiliation_strings":["Diabetes & Endocrinology Emory University Atlanta GA USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes & Endocrinology Emory University Atlanta GA USA","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067359287","display_name":"Michael Albrecht Nauck","orcid":"https://orcid.org/0000-0002-5749-6954","observed_orcids":["https://orcid.org/0000-0002-5749-6954","https://orcid.org/0000-0003-2455-0472"]},"institutions":[{"id":"https://openalex.org/I4210124421","display_name":"Diabeteszentrum Bad Lauterberg","ror":"https://ror.org/02tv28881","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210124421"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. A. Nauck","raw_affiliation_strings":["Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany","institution_ids":["https://openalex.org/I4210124421"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010436601","display_name":"Zachary Skrivanek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Z. Skrivanek","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024563374","display_name":"Zvonko Mili\u010devi\u0107","orcid":"https://orcid.org/0000-0002-6746-901X","observed_orcids":["https://orcid.org/0000-0002-6746-901X","https://orcid.org/0009-0002-8641-023X"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Z. Milicevic","raw_affiliation_strings":["Lilly Research Laboratories Vienna Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories Vienna Austria","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5024563374"],"corresponding_institution_ids":[],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":{"value":5380,"currency":"USD","value_usd":5380},"fwci":10.365,"has_fulltext":true,"cited_by_count":165,"citation_normalized_percentile":{"value":0.98992508,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"17","issue":"9","first_page":"849","last_page":"858"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9860000014305115},{"id":"https://openalex.org/keywords/sitagliptin","display_name":"sitagliptin","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9860000014305115},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8199999928474426},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.7879999876022339},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9539999961853027},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.7110000252723694},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.9679999947547913},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6010000109672546},{"id":"https://openalex.org/keywords/long-term-glycemic-control","display_name":"long-term glycemic control","score":0.7609999775886536},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.36899998784065247},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.47099998593330383},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.7319999933242798},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.4300000071525574},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.3310000002384186}],"concepts":[{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.9734542965888977},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.9620233178138733},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8311625719070435},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6121201515197754},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5750292539596558},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5740219354629517},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.5379190444946289},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5289210081100464},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5013735294342041},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.47931066155433655},{"id":"https://openalex.org/C2778763485","wikidata":"https://www.wikidata.org/wiki/Q419770","display_name":"Dipeptidyl peptidase-4 inhibitor","level":4,"score":0.45610976219177246},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4274426996707916},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.42047688364982605},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.3912162780761719},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3336096405982971},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.324227899312973},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.27595365047454834},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.24342107772827148},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068900","descriptor_name":"Sitagliptin Phosphate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D015431","descriptor_name":"Weight Loss","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/dom.12479","doi":"https://doi.org/10.1111/dom.12479","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12479","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12479","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5008205","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5008205/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Obes Metab","raw_type":"Text"},{"id":"pmid:25912221","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25912221","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1111/dom.12479","doi":"https://doi.org/10.1111/dom.12479","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12479","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12479","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G1347849736","display_name":"Atlanta Clinical and Translational Science Institute (UL1)","funder_award_id":"UL1RR025008","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G1993816215","display_name":null,"funder_award_id":"LY2189265","funder_id":"https://openalex.org/F4320307758","funder_display_name":"Eli Lilly and Company"},{"id":"https://openalex.org/G605911115","display_name":"GENERAL CLINICAL RESEARCH CENTER","funder_award_id":"M01RR000039","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"}],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1992055007.pdf","grobid_xml":"https://content.openalex.org/works/W1992055007.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W135921014","https://openalex.org/W1563830789","https://openalex.org/W1578533615","https://openalex.org/W1968499323","https://openalex.org/W1972057139","https://openalex.org/W1987538170","https://openalex.org/W2003415509","https://openalex.org/W2004409542","https://openalex.org/W2030546890","https://openalex.org/W2054981500","https://openalex.org/W2071835038","https://openalex.org/W2078709678","https://openalex.org/W2090054860","https://openalex.org/W2104252114","https://openalex.org/W2106204981","https://openalex.org/W2107562831","https://openalex.org/W2107949845","https://openalex.org/W2109677274","https://openalex.org/W2113367996","https://openalex.org/W2116124690","https://openalex.org/W2118710260","https://openalex.org/W2124620553","https://openalex.org/W2126807972","https://openalex.org/W2144724140","https://openalex.org/W2152984355","https://openalex.org/W2154433510","https://openalex.org/W2170606300","https://openalex.org/W2181829228","https://openalex.org/W2190748907","https://openalex.org/W2634243099","https://openalex.org/W4241299322","https://openalex.org/W4252564070","https://openalex.org/W7073874324"],"related_works":["https://openalex.org/W2090054860","https://openalex.org/W7096540307","https://openalex.org/W2135285778","https://openalex.org/W2004269133","https://openalex.org/W906438903","https://openalex.org/W1559082056","https://openalex.org/W2610688436","https://openalex.org/W2261901121","https://openalex.org/W2133536834","https://openalex.org/W2098786409"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"compare":[2],"the":[3,11,63,88,98],"once-weekly":[4],"glucagon-like":[5],"peptide-1":[6],"(GLP-1)":[7],"receptor":[8],"dulaglutide":[9,35,94,138,141,151,160,192,236],"with":[10,72,159,168,191,249],"dipeptidyl":[12],"peptidase-4":[13],"(DPP-4)":[14],"inhibitor":[15],"sitagliptin":[16,41,96,172,198,245],"after":[17],"104":[18,45,106,247],"weeks":[19,46,107],"of":[20,69],"treatment.":[21],"METHODS:":[22],"This":[23],"AWARD-5":[24],"study":[25],"was":[26,62,157],"a":[27],"multicentre,":[28],"double-blind":[29],"trial":[30],"that":[31],"randomized":[32],"participants":[33,71],"to":[34],"(1.5":[36],"or":[37,40,47],"0.75":[38,142,169,195],"mg)":[39],"100":[42],"mg":[43,143,162,170,196,238],"for":[44,51,93,137],"placebo":[48],"(reported":[49],"separately)":[50],"26":[52],"weeks.":[53],"Change":[54],"in":[55,103,240],"glycated":[56],"haemoglobin":[57],"(HbA1c)":[58],"concentration":[59],"from":[60],"baseline":[61],"primary":[64],"efficacy":[65],"measure.":[66],"A":[67],"total":[68],"1098":[70],"HbA1c":[73,104],"concentrations":[74],"\u22657.0%":[75],"(\u226553.0":[76],"mmol/mol)":[77,81,128,136],"and":[78,84,95,129,144,166,179,194,201,207,213,221,235],"\u22649.5%":[79],"(\u226480.3":[80],"were":[82,108,188,224],"randomized,":[83],"657":[85],"(59.8%)":[86],"completed":[87],"study.":[89],"We":[90],"report":[91],"results":[92],"at":[97,105,246],"final":[99],"endpoint.":[100],"RESULTS:":[101],"Changes":[102],"(least":[109],"squares":[110],"mean":[111],"\u00b1":[112,116,119,123,126,131,134,174,177,181],"standard":[113],"error)":[114],"-0.99":[115],"0.06%":[117,132],"(-10.82":[118],"0.66":[120,135],"mmol/mol),":[121],"-0.71":[122],"0.07%":[124],"(-7.76":[125],"0.77":[127],"-0.32":[130],"(-3.50":[133],"1.5":[139,161,193,237],"mg,":[140],"sitagliptin,":[145],"respectively":[146],"(p":[147,163],"<":[148,164],"0.001,":[149],"both":[150],"doses":[152,230],"vs":[153,203,209,215],"sitagliptin).":[154],"Weight":[155],"loss":[156],"greater":[158,241],"0.001)":[165],"similar":[167,225],"versus":[171,197,244],"(2.88":[173],"0.25,":[175],"2.39":[176],"0.26":[178],"1.75":[180],"0.25":[182],"kg,":[183],"respectively).":[184,217],"Gastrointestinal":[185],"adverse":[186],"events":[187],"more":[189],"common":[190],"(nausea":[199],"17":[200],"15%":[202],"7%,":[204],"diarrhoea":[205],"16":[206],"12%":[208],"6%,":[210],"vomiting":[211],"14":[212],"8%":[214],"4%":[216],"Pancreatic,":[218],"thyroid,":[219],"cardiovascular":[220],"hypersensitivity":[222],"safety":[223],"across":[226],"groups.":[227],"CONCLUSIONS:":[228],"Dulaglutide":[229],"provided":[231],"superior":[232],"glycaemic":[233],"control":[234],"resulted":[239],"weight":[242],"reduction":[243],"weeks,":[248],"acceptable":[250],"safety.":[251]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1992055007","counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":22},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":13},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":17},{"year":2018,"cited_by_count":18},{"year":2017,"cited_by_count":15},{"year":2016,"cited_by_count":14},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
